A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib
plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The
LOLA trial
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano